[{"id":"205a8549-254c-458b-bd69-60477d827fd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04380545","created_at":"2023-12-11T15:16:05.793Z","updated_at":"2025-02-25T15:18:37.255Z","phase":"Phase 1/2","brief_title":"Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer","source_id_and_acronym":"NCT04380545","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • fluorouracil topical • Novaferon (recombinant anti-tumor and anti-virus protein)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/13/2021","start_date":" 01/13/2021","primary_txt":" Primary completion: 02/28/2026","primary_completion_date":" 02/28/2026","study_txt":" Completion: 02/28/2026","study_completion_date":" 02/28/2026","last_update_posted":"2025-02-11"}]